CN101070304B - 喹啉衍生物及其作为分枝杆菌抑制剂的应用 - Google Patents

喹啉衍生物及其作为分枝杆菌抑制剂的应用 Download PDF

Info

Publication number
CN101070304B
CN101070304B CN2007101049477A CN200710104947A CN101070304B CN 101070304 B CN101070304 B CN 101070304B CN 2007101049477 A CN2007101049477 A CN 2007101049477A CN 200710104947 A CN200710104947 A CN 200710104947A CN 101070304 B CN101070304 B CN 101070304B
Authority
CN
China
Prior art keywords
compound
alkyl
application
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2007101049477A
Other languages
English (en)
Chinese (zh)
Other versions
CN101070304A (zh
Inventor
杰罗姆·埃米尔·乔治斯·吉耶蒙特
J·F·E·范格斯特尔
M·G·韦内
L·F·B·德克拉纳
D·F·J·韦尼耶
F·C·奥德斯
I·C·F·科索卡
K·J·L·M·安蒂雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101070304(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101070304A publication Critical patent/CN101070304A/zh
Application granted granted Critical
Publication of CN101070304B publication Critical patent/CN101070304B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2007101049477A 2002-07-25 2003-07-18 喹啉衍生物及其作为分枝杆菌抑制剂的应用 Expired - Lifetime CN101070304B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
US60/398711 2002-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB038177137A Division CN1325475C (zh) 2002-07-25 2003-07-18 喹啉衍生物及其作为分枝杆菌抑制剂的应用

Publications (2)

Publication Number Publication Date
CN101070304A CN101070304A (zh) 2007-11-14
CN101070304B true CN101070304B (zh) 2011-10-26

Family

ID=31188461

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007101049477A Expired - Lifetime CN101070304B (zh) 2002-07-25 2003-07-18 喹啉衍生物及其作为分枝杆菌抑制剂的应用
CNB038177137A Expired - Lifetime CN1325475C (zh) 2002-07-25 2003-07-18 喹啉衍生物及其作为分枝杆菌抑制剂的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB038177137A Expired - Lifetime CN1325475C (zh) 2002-07-25 2003-07-18 喹啉衍生物及其作为分枝杆菌抑制剂的应用

Country Status (37)

Country Link
US (1) US7498343B2 (cg-RX-API-DMAC7.html)
EP (2) EP2301544B1 (cg-RX-API-DMAC7.html)
JP (1) JP4484703B2 (cg-RX-API-DMAC7.html)
KR (1) KR100733577B1 (cg-RX-API-DMAC7.html)
CN (2) CN101070304B (cg-RX-API-DMAC7.html)
AP (1) AP2421A (cg-RX-API-DMAC7.html)
AR (1) AR040673A1 (cg-RX-API-DMAC7.html)
AT (1) ATE463482T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003262529B2 (cg-RX-API-DMAC7.html)
BE (1) BE2014C051I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0312927B8 (cg-RX-API-DMAC7.html)
CA (1) CA2493225C (cg-RX-API-DMAC7.html)
CY (3) CY1111882T1 (cg-RX-API-DMAC7.html)
DE (1) DE60332023D1 (cg-RX-API-DMAC7.html)
DK (2) DK2301544T3 (cg-RX-API-DMAC7.html)
EA (1) EA008937B1 (cg-RX-API-DMAC7.html)
ES (2) ES2343458T3 (cg-RX-API-DMAC7.html)
FR (1) FR14C0060I2 (cg-RX-API-DMAC7.html)
HR (2) HRP20120190B1 (cg-RX-API-DMAC7.html)
HU (1) HUS1400047I1 (cg-RX-API-DMAC7.html)
IL (2) IL166457A (cg-RX-API-DMAC7.html)
IS (1) IS2914B (cg-RX-API-DMAC7.html)
LU (1) LU92520I2 (cg-RX-API-DMAC7.html)
ME (1) ME00131B (cg-RX-API-DMAC7.html)
MX (1) MXPA05001052A (cg-RX-API-DMAC7.html)
MY (1) MY143564A (cg-RX-API-DMAC7.html)
NL (1) NL300684I2 (cg-RX-API-DMAC7.html)
NO (2) NO329935B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ538391A (cg-RX-API-DMAC7.html)
PL (1) PL222801B1 (cg-RX-API-DMAC7.html)
PT (2) PT1527050E (cg-RX-API-DMAC7.html)
RS (1) RS52431B (cg-RX-API-DMAC7.html)
SI (2) SI1527050T1 (cg-RX-API-DMAC7.html)
TW (1) TWI323730B (cg-RX-API-DMAC7.html)
UA (1) UA82198C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004011436A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500680B (cg-RX-API-DMAC7.html)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51074B (sr) * 2004-01-23 2010-10-31 Janssen Pharmaceutica N.V. Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora
ATE392423T1 (de) 2004-01-23 2008-05-15 Janssen Pharmaceutica Nv Substituierte chinoline und deren verwendung als inhibitoren von mycobakterien
UA83875C2 (ru) 2004-01-29 2008-08-26 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006035051A1 (en) * 2004-09-28 2006-04-06 Janssen Pharmaceutica N.V. A bacterial atp synthase binding domain
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
BG66437B1 (bg) * 2004-12-24 2014-07-31 Janssen Pharmaceutica N.V. Използване на хинолинови съединения за лечение на латентна туберкулоза
ME01445B (me) * 2005-05-25 2013-12-20 Janssen Pharmaceutica Nv PROCES ZA PRIPREMU (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETIL]-2-METOKSI-ALF A-l-NAFTALENIL-BETA-FENIL-3-KINOLINETANOLA
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
LT1898909T (lt) * 2005-06-28 2017-02-10 Janssen Pharmaceutica Nv Chinolino dariniai kaip antibakteriniai agentai
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
WO2007022946A1 (de) * 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
DK2841425T3 (en) 2012-04-27 2016-06-27 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
AP2015008503A0 (en) 2012-12-21 2015-06-30 Janssen Sciences Ireland Uc Antibacterial compounds
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
EP3170810B1 (en) * 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CN114129526A (zh) 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN108347945B (zh) * 2015-04-29 2021-03-23 以色列农业和农村发展部农业研究组织(范卡尼中心) 抗植物致病组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
RS63201B1 (sr) 2015-07-02 2022-06-30 Janssen Sciences Ireland Unlimited Co Antibakterijska jedinjenja
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
WO2017015793A1 (zh) * 2015-07-24 2017-02-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN108699047B (zh) * 2016-03-03 2022-03-11 科学与工业研究委员会 作为抗分枝杆菌药剂的取代的橙酮生物碱
CA3226824A1 (en) * 2016-03-07 2017-09-14 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
KR20190018681A (ko) 2016-06-16 2019-02-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균제로서의 헤테로고리 화합물
EA201990043A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Антибактериальные соединения
BR112019017901A2 (pt) 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação
PE20200336A1 (es) 2017-07-14 2020-02-14 Janssen Pharmaceutica Nv Formulaciones a largo plazo
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
CA3149868A1 (en) 2019-09-13 2021-03-18 Jerome Emile Georges Guillemont Antibacterial compounds
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
US20220389008A1 (en) 2019-09-30 2022-12-08 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
BR112022005449A2 (pt) 2019-09-30 2022-06-21 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
MX2022008005A (es) 2019-12-27 2022-07-21 Tecnimede Sociedade Tecnico Medicinal Sa Quinolinas antibacterianas.
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
CA3182854A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
PE20231296A1 (es) 2020-07-09 2023-08-22 Janssen Pharmaceutica Nv Formulaciones a largo plazo
JP2023549605A (ja) 2020-11-12 2023-11-28 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ
CN117396475A (zh) 2021-03-16 2024-01-12 爱尔兰詹森科学公司 抗菌化合物
MX2023010948A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3212074A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3223626A1 (en) 2021-06-29 2023-01-05 Augusto Eugenio Pardal Filipe Heterocyclic compounds for the treatment of tuberculosis
KR20240090864A (ko) 2021-10-28 2024-06-21 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
WO2023217279A1 (zh) * 2022-05-13 2023-11-16 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
EP4593834A1 (en) 2022-09-28 2025-08-06 JANSSEN Pharmaceutica NV Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20240199608A1 (en) * 2022-11-15 2024-06-20 Eli Lilly And Company Ahr agonists
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria
WO2025181475A1 (en) 2024-02-27 2025-09-04 The University Of Liverpool Novel tuberculosis sterilization formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270123A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
HUP0003364A3 (en) * 1997-06-19 2002-03-28 Sepracor Inc Marlborough Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1999037365A1 (en) * 1998-01-23 1999-07-29 Fire Armour Pte Ltd. Nozzle with axially and perpendicularly directed apertures
ES2201674T3 (es) * 1998-01-26 2004-03-16 Smithkline Beecham Plc Derivados de quinolina con propiedades antibacterianas.
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
HRP20120190A2 (hr) 2012-05-31
BRPI0312927B8 (pt) 2021-05-25
PL375523A1 (en) 2005-11-28
DK1527050T3 (da) 2010-07-19
NO2014021I1 (no) 2014-08-20
NO20050476L (no) 2005-01-27
UA82198C2 (uk) 2008-03-25
BR0312927A (pt) 2005-07-12
ES2343458T3 (es) 2010-08-02
FR14C0060I2 (fr) 2015-11-20
IS7620A (is) 2004-12-29
US20050148581A1 (en) 2005-07-07
EP1527050B1 (en) 2010-04-07
TW200410939A (en) 2004-07-01
HRP20120190A8 (hr) 2012-07-31
DK2301544T3 (da) 2013-01-02
KR100733577B1 (ko) 2007-06-29
CN1671667A (zh) 2005-09-21
WO2004011436A1 (en) 2004-02-05
CY1111882T1 (el) 2015-11-04
SI1527050T1 (sl) 2010-08-31
AU2003262529B2 (en) 2009-11-19
SI2301544T1 (sl) 2013-01-31
NZ538391A (en) 2005-10-28
JP2006504658A (ja) 2006-02-09
DE60332023D1 (de) 2010-05-20
CA2493225C (en) 2012-03-20
RS52431B (sr) 2013-02-28
MEP9208A (en) 2010-06-10
AP2421A (en) 2012-06-08
EA008937B1 (ru) 2007-10-26
NO329935B1 (no) 2011-01-24
IL202655A (en) 2012-04-30
CY1113497T1 (el) 2016-06-22
JP4484703B2 (ja) 2010-06-16
CA2493225A1 (en) 2004-02-05
HRP20050045B1 (hr) 2013-09-30
BRPI0312927B1 (pt) 2018-07-10
RS20050058A (sr) 2007-06-04
PL222801B1 (pl) 2016-09-30
HUS1400047I1 (hu) 2016-09-28
EP2301544B1 (en) 2012-09-19
IS2914B (is) 2014-12-15
US7498343B2 (en) 2009-03-03
NO2014021I2 (cg-RX-API-DMAC7.html) 2014-08-20
EP1527050A1 (en) 2005-05-04
TWI323730B (en) 2010-04-21
KR20050033607A (ko) 2005-04-12
BE2014C051I2 (cg-RX-API-DMAC7.html) 2022-08-09
IL166457A (en) 2011-10-31
NL300684I2 (cg-RX-API-DMAC7.html) 2016-10-11
HK1113795A1 (en) 2008-10-17
EA200500257A1 (ru) 2005-06-30
HRP20120190B1 (hr) 2017-06-02
CN101070304A (zh) 2007-11-14
AR040673A1 (es) 2005-04-13
MXPA05001052A (es) 2005-04-08
MY143564A (en) 2011-05-31
PT2301544E (pt) 2012-12-10
IL166457A0 (en) 2006-01-15
HRP20050045A2 (en) 2006-06-30
ZA200500680B (en) 2006-08-30
ME00131B (me) 2010-10-10
AP2005003210A0 (en) 2005-03-31
AU2003262529A1 (en) 2004-02-16
CY2014033I1 (el) 2016-04-13
EP2301544A1 (en) 2011-03-30
CN1325475C (zh) 2007-07-11
ES2395237T3 (es) 2013-02-11
HK1083496A1 (en) 2006-07-07
PT1527050E (pt) 2010-06-22
CY2014033I2 (el) 2016-04-13
ATE463482T1 (de) 2010-04-15
FR14C0060I1 (cg-RX-API-DMAC7.html) 2014-10-10
LU92520I2 (fr) 2015-11-02

Similar Documents

Publication Publication Date Title
CN101070304B (zh) 喹啉衍生物及其作为分枝杆菌抑制剂的应用
CN101553470A (zh) 抗菌的喹啉衍生物
CN1910154B (zh) 用作分枝杆菌抑制剂的喹啉衍生物
CN103142595B (zh) 用于治疗潜伏性结核的喹啉衍生物
CN101232884B (zh) 作为抗菌剂的喹啉衍生物
JP2007502861A (ja) 抗菌方法及び組成物
CN101277695A (zh) 作为抗菌剂的喹啉衍生物
CN101547907A (zh) 抗菌的喹啉衍生物
AU2016205187B2 (en) Concise synthesis of urea derivatives of amphotericin B
TWI427065B (zh) 抗菌之喹啉衍生物
CN101541752A (zh) 抗菌的喹啉衍生物
EP1898909B1 (en) Quinoline derivatives as antibacterial agents
TWI387457B (zh) 作為抗細菌劑之喹啉衍生物（二）
CN101277698A (zh) 作为抗菌剂的喹啉衍生物
HUE031268T2 (en) Quinoline derivatives as antibacterial agents
JP5349730B2 (ja) 抗バクテリア剤としてのキノリン誘導体
HK1113795B (en) Quinoline derivatives and their use as mycobacterial inhibitors
HK1083496B (en) Quinoline derivatives and their use as mycobacterial inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1113795

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1113795

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20111026

CX01 Expiry of patent term